Is there excess mortality in women screened with mammography: A meta-analysis of non-breast cancer mortality

Trials

Volumn 14, Issue 1, 2013, Pages

  Erpeldinger, Sylvie ^a   Fayolle, Laure ^a   Boussageon, Rémy ^a   Flori, Marie ^a   Lainé, Xavier ^a   Moreau, Alain ^a   Gueyffier, François ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

Breast cancer; France; Mammography; Meta analysis; Mortality; Screening

Indexed keywords

ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SCREENING; CLINICAL EXAMINATION; FOLLOW UP; HUMAN; MAMMOGRAPHY; MEDLINE; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW;

ADULT; AGED; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84887068345     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-368     Document Type: Article

References (50)

1. WHO The global burden of disease: 2004 update 2008, Geneva: World Health Organization, http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf, accessed 2012 Jun 12, WHO.
2. Dossiers-thematiques/Maladies-chroniques-et traumatismes/Cancers/Surveillance-epidemiologique-des-cancers/Estimations-de-l-incidence-et-de-la-mortalite/Estimation-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-entre-1980-et-2012-Tumeurs-solides http://www.invs.sante.fr/ (accessed 27 August 2013).
3. Belot A, Arveux P, Bara S, Benhamou E, Binder-Foucard F, Bossard N, Bouvier AM, Buemi A, Chérié-Challine L, Colonna M, Danzon A, Daubisse L, Delafosse P, Estève J, Faivre J, Galateau-Sallé F, Grosclaude P, Guizard AV, Hédelin G, Janoray I, Jougla E, Launoy G, Le Stang N, Maynadié M, Molinié F, Monnereau A, Raverdy N, Remontet L, Schvartz C, Trétarre B, Troussard X, Velten M, et al. Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2005 2008, 56-59. Saint-Maurice (France): Institut de veille sanitaire.
4. InVS [Internet] Programme national de dépistage organisé du cancer du sein. Evaluation des programmes de dépistage des cancers 2006, http://www.invs.sante.fr/surveillance/cancers_depistage/evaluation_sein_programme.htm, accessed 2012 Jun 13, InVS [Internet].
5. Groupe collaboratif, Structures de gestion du dépistage, Réseau français des registres de cancers Francim, Centres de lutte contre le cancer, Institut de veille sanitaire Estimation de l'impact du dépistage organisé sur la mortalité par cancer du sein: contexte, méthodologie et faisabilité 2007, 102. Saint-Maurice (France): Institut de veille sanitaire, http://212.234.146.165/publications/2007/depistage_cancer_sein/depistage_cancer_sein.pdf, accessed 2012 Jun 12, Groupe collaboratif, Structures de gestion du dépistage, Réseau français des registres de cancers Francim, Centres de lutte contre le cancer, Institut de veille sanitaire.
6. Groupe Technique National Cahier des charges pour les radiologues. Cahier des charges du dépistage organisé du cancer du sein 2006, Ilkkirch: Société française de Sénologie et de Pathologie Mammaire (SFSPM), http://www.senologie.com/site/pdf/24-05-06-cdc_radiologues.pdf, accessed 2012 Jun 13, Groupe Technique National.
7. Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002, 359:909-919. 10.1016/S0140-6736(02)08020-0, 11918907.
8. Nyström L, Wall S, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, Andersson J, Bjurstam N, Fagerberg G, Frisell J, Tabar L, Larsson L-G, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993, 341:973-978. 10.1016/0140-6736(93)91067-V, 8096941.
9. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995, 11:149-154.
10. Demissie K, Mills OF, Rhoads GG. Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography. J Clin Epidemiol 1998, 51:81-91. 10.1016/S0895-4356(97)00243-6, 9474068.
11. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan B, Nygren P, Humphrey L, et al. Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force [Internet] 2009, Rockville (MD): Agency for Healthcare Research and Quality (US), http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0005880/pdf/TOC.pdf (accessed 12 Jun 2012).
12. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009, 4:CD001877.
13. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011, 1:CD001877.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009, 6(6):e1000097. doi:10.1371/journal.pmed1000097. http://www.prisma-statement.org/2.1.2 - PRISMA 2009 Checklist.pdf, 2707599, 19621072, The PRISMA Group.
15. Berglund G, Nilsson P, Eriksson KF, Nilsson JA, Hedblad B, Kristenson H, Lindgârde F, et al. Long-term outcome of the Malmö preventive project: mortality and cardiovascular morbidity. J Intern Med 2000, 247:19-29. 10.1046/j.1365-2796.2000.00568.x, 10672127.
16. Ng EH, Ng FC, Tan PH, Low SC, Chiang G, Tan KP, Seow A, Emmanuel S, Tan CH, Ho GH, Ng LT, Wilde CC, et al. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project. Cancer 1998, 82:1521-1528. 10.1002/(SICI)1097-0142(19980415)82:8<1521::AID-CNCR14>3.0.CO;2-6, 9554530.
17. Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, Miller AB, Daniel EE, Gupta S, Uplap P, Thakur MH, Ramani S, Kerkar R, Ganesh B, Shastri SS, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010, 12:976-984.
18. Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen 1999, 6:144-148. 10.1136/jms.6.3.144, 10572845.
19. Moss S, Waller M, Anderson TJ, Cuckle H. Trial Management Group. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 2005, 92:955-960. 10.1038/sj.bjc.6602395, 2361918, 15726103.
20. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. CMAJ 1992, 147:1459-1476. 1336543, 1423087.
21. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 1992, 147:1477-1488. 1336544, 1423088.
22. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000, 92:1490-1499. 10.1093/jnci/92.18.1490, 10995804.
23. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up: a randomized screening trial of mammography in women Age 40 to 49 years. Ann Intern Med 2002, 137:305-312. 10.7326/0003-4819-137-5_Part_1-200209030-00005, 12204013.
24. Bjurstam N, Björneld L, Warwick J, Sala E, Duffy SW, Nyström L, Walker N, Cahlin E, Eriksson O, Hafstrôm LO, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Salander H, Sâve-Sôderbergh J, Wahlin T, et al. The Gothenburg breast screening trial. Cancer 2003, 97:2387-2396. 10.1002/cncr.11361, 12733136.
25. Bjurstam N, Björneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, Hafstrôm LO, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Sâve-Sôderbergh J, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 1997, 80:2091-2099. 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-#, 9392331.
26. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfùsson B, et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ 1988, 297:943-948. 10.1136/bmj.297.6654.943, 1834636, 3142562.
27. Andersson I, Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. J Natl Cancer Inst Monogr 1997, 22:63-67.
28. Frisell J, Lidbrink E, Hellström L, Rutqvist LE. Follow-up after 11 years - update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Res Treat 1997, 45:263-270. 10.1023/A:1005872617944, 9386870.
29. Tabar L, Fagerberg G, Duffy SW, Day NE. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 1989, 43:107-114. 10.1136/jech.43.2.107, 1052811, 2512366.
30. Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995, 75:2507-2517. 10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H, 7736395.
31. Tabar L, Faberberg G, Day NE, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987, 55:547-551. 10.1038/bjc.1987.112, 2001715, 3606947.
32. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. Natl Cancer Inst Monogr 1985, 67:65-74.
33. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982, 69:349-355.
34. Aron JL, Prorok PC. An analysis of the mortality effect in a breast cancer screening study. Int J Epidemiol 1986, 15:36-43. 10.1093/ije/15.1.36, 3957541.
35. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, Muir BB, Prescott RJ, Smith A, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet 1999, 353:1903-1908. 10.1016/S0140-6736(98)07413-3, 10371567.
36. Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 1996, 312:273-276. 10.1136/bmj.312.7026.273, 2349888, 8611781.
37. Johns LE, Moss SM. False-positive results in the randomized controlled trial of mammographic screening from age 40 (« Age » trial). Cancer Epidemiol Biomarkers Prev 2010, 19:2758-2764. 10.1158/1055-9965.EPI-10-0623, 2978129, 20837718.
38. Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer 2004, 101:1501-1507. 10.1002/cncr.20528, 15378474.
39. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998, 338:1089-1096. 10.1056/NEJM199804163381601, 9545356.
40. Lastier D, Salines E, Danzon A. Programme de dépistage du cancer du sein en France: résultats 2007-2008, évolutions depuis 2004 2011, 12. Saint-Maurice: Institut de veille Sanitaire.
41. Brodersen J, Thorsen H, Kreiner S. Validation of a condition-specific measure for women having an abnormal screening mammography. Value Health 2007, 10:294-304. 10.1111/j.1524-4733.2007.00184.x, 17645684.
42. Barton MB, Moore S, Polk S, Shtatland E, Elmore JG, Fletcher SW. Increased patient concern after false-positive mammograms: clinician documentation and subsequent ambulatory visits. J Gen Intern Med 2001, 16:150-156. 10.1111/j.1525-1497.2001.00329.x, 1495181, 11318909.
43. Njor SH, Olsen AH, Blichert_Toft M, Schwartz W, Vejborg I, Lynge E. Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ 2013, 346:f1064. 10.1136/bmj.f1064, 3582341, 23444414.
44. Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer 2009, 45:3166-3171. 10.1016/j.ejca.2009.06.014, 19879130.
45. Barratt A, Howard K, Irwig L, Salkeld G, Houssami N. Model of outcomes of screening mammography: information to support informed choices. BMJ 2005, 330:936. 10.1136/bmj.38398.469479.8F, 556337, 15755755.
46. Junod B, Zahl PH, Kaplan RM, Olsen J, Greenland S. An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts. BMC Cancer 2011, 11:401. 10.1186/1471-2407-11-401, 3188513, 21936933.
47. Procter M, Suter TM, De Azambuja E, Dafni U, Van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Tsang-Wu Liu W, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, Van Veldhuisen DJ, Piccart-Gebbar MJ, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010, 28:3422-3428. 10.1200/JCO.2009.26.0463, 20530280.
48. Cutuli B, de Lafontan B, Lemanski C. Effets secondaires des traitements loco régionaux. 32èmes journées de la SFSPM 2010, Strasbourg FRANCE: Société française de sénologie et de pathologie mammaire, DaTeBe, Courbevoie (FRA).
49. National Research Council Biologic Effects of Ionizing Radiation VII: Health Risks from Exposure to Low Levels of Ionizing Radiation 2005, Washington DC: National Academic of Science, National Research Council.
50. Boissel JP, Kahoul R, Amsallem E, Gueyffier F, Haugh M, Boissel FH. Towards personalized medicine: exploring the consequences of the effect model-based approach. Pers Med 2011, 8:581-586.